Effect of mirikizumab on clinical and endoscopic outcomes after 1 anti-TNF failure in patients with moderately to severely active Ulcerative Colitis

被引：0
|
作者：
Hart, A. [1 ,2 ]
Martin-Arranz, M. D. [3 ]
Laharie, D. [4 ]
Matsuoka, K. [5 ]
Dhesi, E. [6 ]
Redondo, I. [6 ]
Baygani, S. [6 ]
Zaremba-Pechmann, L. [7 ]
Samaan, K. [6 ]
Navabi, S. [8 ]
机构：
[1] St Marks Hosp, London, England
[2] Imperial Coll, Dept Metab Digest & Reprod, London, England
[3] Hosp La Paz Inst Hlth Res, Dept Gastroenterol, Madrid, Spain
[4] Univ Bordeaux, Ctr Hosp Univ Bordeaux, Hop Haut Leveque, Bordeaux, France
[5] Toho Univ, Div Gastroenterol & Hepatol, Sakura Med Ctr, Dept Internal Med, Sakura, Japan
[6] Eli Lilly & Co, Indianapolis, IN 46285 USA
[7] HaaPACS GmBH, Stat, Schriesheim, Germany
[8] United Med Doctors, Gastroenterol Hepatol & Obes Med, Long Beach, CA USA
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
OP14
引用
收藏
页码：I27 / I28
页数：2
相关论文
共 50 条
  • [31] Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials
    D'Haens, Geert
    Higgins, Peter D. R.
    Peyrin-Biroulet, Laurent
    Sands, Bruce E.
    Lee, Scott
    Moses, Richard E.
    Redondo, Isabel
    Escobar, Rodrigo
    Gibble, Theresa Hunter
    Keohane, Anthony
    Morris, Nathan
    Zhang, Xin
    Arora, Vipin
    Kobayashi, Taku
    INFLAMMATORY BOWEL DISEASES, 2024, 30 (12) : 2335 - 2346
  • [32] Trajectories of response in patients with moderately-to-severely active ulcerative colitis treated with mirikizumab: Results from the LUCENT-1 study
    Schreiber, S. W.
    Clemow, D. B.
    Keohane, A.
    Zhu, B.
    Ritter, T.
    Regueiro, M.
    Hudesman, D.
    Chen, Y. F.
    Owen, C.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I1975 - I1976
  • [33] Adalimumab for Induction of Clinical Remission in Moderately to Severely Active Ulcerative Colitis
    Reinisch, Walter
    Sandborn, William J.
    Hommes, Daniel W.
    D'Haens, Geert R.
    Hanauer, Stephen B.
    Schreiber, Stefan
    Panaccione, Remo
    Fedorak, Richard N.
    Tighe, Mary Beth
    Huang, Bidan
    Lazar, Andreas
    GASTROENTEROLOGY, 2010, 138 (05) : S114 - S115
  • [34] BUDGET IMPACT OF MIRIKIZUMAB-MRKZ IN THE TREATMENT OF ADULT PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED STATES
    Stargardter, Matthew
    Upadhyay, Navneet
    Raj, Sayooj
    Fisher, Deborah
    Creveling, Thomas
    Bires, Nicholas
    Johnson, Nate
    Milev, Sandra
    GASTROENTEROLOGY, 2024, 166 (03) : S60 - S60
  • [35] The Effect of Mirikizumab on Fecal Calprotectin and C-Reactive Protein in Phase 3 Studies of Patients With Moderately-to-Severely Active Ulcerative Colitis
    Siegmund, Britta
    Sands, Bruce E.
    Samaan, Karen
    Li, Xingyuan
    Morris, Nathan
    Gibble, Theresa Hunter
    Redondo, Isabel
    Lissoos, Trevor
    D'Haens, Geert
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S543 - S544
  • [36] EFFICACY OF INFLIXIMAB AFTER FAILURE OF SUBCUTANEOUS ANTI-TNF AGENT IN PATIENTS WITH ULCERATIVE COLITIS: A MULTICENTER STUDY
    Streichenberger, Aurelie
    Pariente, Benjamin
    Bozon, Anne
    Arab, Nadia
    Amiot, Aurelien
    Vuitton, Lucine
    Tilmant, Marion
    Nachury, Maria
    Altwegg, Romain
    Delasalle, Thibault
    Gagniere, Charlotte
    Boivineau, Gregoire
    Fumery, Mathurin
    Wils, Pauline
    de Chambrun, Guillaume Pineton
    Hebuterne, Xavier
    Pereira, Bruno
    Bommelaer, Gilles
    Buisson, Anthony
    GASTROENTEROLOGY, 2018, 154 (06) : S834 - S834
  • [37] Efficacy of infliximab after failure of subcutaneous anti-TNF agents in patients with ulcerative colitis: A multicentre study
    Streichenberger, A.
    Pariente, B.
    Bozon, A.
    Arab, N.
    Amiot, A.
    Vuitton, L.
    Tilmant, M.
    Nachury, M.
    Altwegg, R.
    Delasalle, T.
    Gagniere, C.
    Gregoire, B.
    Fumery, M.
    Wils, P.
    de Chambrun, G. Pineton
    Hebuterne, X.
    Pereira, B.
    Bommelaer, G.
    Buisson, A.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S291 - S291
  • [38] Mirikizumab Improves Patient Assessments of Disease Severity and Change in Disease Activity in Patients With Moderately-to-Severely Active Ulcerative Colitis
    Travis, Simon
    Wu, Jianmin
    Sapin, Christophe
    Gibble, Theresa Hunter
    Hibi, Toshifumi
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 : S30 - S31
  • [39] Sustained Symptom Control With Mirikizumab in Patients With Moderately-to-Severely Active Ulcerative Colitis in the LUCENT-2 Maintenance Trial
    Dignass, Axel
    Danese, Silvio
    Matsuoka, Katsuyoshi
    Ferrante, Marc
    Long, Millie
    Redondo, Isabel
    Gibble, Theresa Hunter
    Moses, Richard
    Li, Xingyuan
    Morris, Nathan
    Milch, Catherine
    Abreu, Maria T.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S558 - S558
  • [40] BUDGET IMPACT OF MIRIKIZUMAB-MRKZ IN THE TREATMENT OF ADULT PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED STATES
    Stargardter, Matthew
    Upadhyay, Navneet
    Raj, Sayooj
    Fisher, Deborah
    Creveling, Thomas
    Bires, Nicholas
    Johnson, Nate
    Milev, Sandra
    INFLAMMATORY BOWEL DISEASES, 2024, 30 : S43 - S44
12345